American Journal of Kidney Diseases
Volume 51, Issue 3 , Pages 353-357, March 2008

CKD in the Elderly—Old Questions and New Challenges: World Kidney Day 2008

  • Lesley A. Stevens, MD, MS

      Affiliations

    • Tufts–New England Medical Center, Boston, Massachusetts
    • Corresponding Author InformationAddress correspondence to Lesley A. Stevens, MD, Department of Nephrology, Tufts-New England Medical Center, 750 Washington St, Boston, MA 02111.
    • ,
  • Josef Coresh, MD, PhD

      Affiliations

    • Johns Hopkins Medical Institutions, Baltimore, Maryland
    • ,
  • Andrew S. Levey, MD

      Affiliations

    • Tufts–New England Medical Center, Boston, Massachusetts

Article Outline

 

Related Articles, pp. 358 and 373

Thursday, March 13, 2008 is World Kidney Day! World Kidney Day was proposed by the International Society of Nephrology and International Federation of Kidney Foundations in 2006 to broadcast a message about kidney diseases to the public, government health officials, general physicians, allied health professionals, individuals, and families. In 2007, the message on World Kidney Day was that kidney disease is common, harmful, and treatable.1 This issue of AJKD contains articles from around the world about the importance of chronic kidney disease (CKD), attesting to the growing recognition of CKD as a global public health problem. In this editorial, we highlight CKD in the elderly as a new challenge for research, clinical practice, and public health.

Back to Article Outline

Background 

As the world’s population ages, a major challenge is to unravel the pathways to disease and disability in older persons. The elderly are the fastest growing subset of the US population, with the number of adults over 65 years of age expected to approach approximately 20% of the population by 2030.2 Age-associated increases in chronic disease and disability have led to a significant financial burden on the health care system, due to increases in testing, medication usage, hospitalizations, and institutionalization.3 CKD has recently been recognized as one of a number of chronic diseases primarily affecting the elderly; early stages are silent yet associated with substantially increased risk for cardiovascular disease, while later stages are also associated with a wide range of additional complications including kidney failure. The full extent of the burden of CKD is not known and many questions remain unanswered. Understanding the prevalence, causes, and associations of CKD with other chronic diseases in the elderly is essential for effective treatment and prevention.

Back to Article Outline

Two Recent Studies 

Recent studies from the United States and China provide new information about the prevalence of CKD in the elderly. In JAMA, Coresh and colleagues used data from the US National Health and Nutrition Examination Survey (NHANES) to estimate the prevalence of CKD among noninstitutionalized adults (aged ≥ 20 years).4 They found an increase in prevalence from approximately 10% in the period from 1988 to 1994 to 13% in the period from 1999 to 2004, corresponding to 26 million people in the year 2000. Among individuals aged 70 years or older, the prevalence of CKD increased from 38% to 47% (Fig 1, right bars). For this analysis, kidney damage was defined as persistent albuminuria (spot urine albumin-creatinine ratio > 30 mg/g), and glomerular filtration rate (GFR) was estimated from serum creatinine using an assay traceable to isotope dilution mass spectroscopy (IDMS) and the Modification of Diet in Renal Disease (MDRD) Study equation re-expressed for use with standardized creatinine.5

  • View full-size image.
  • Figure 1. 

    Prevalence of CKD stages by age groups in NHANES 1999 to 2004 and the Beijing study.4, 6 For NHANES, CKD was defined as persistent albuminuria (spot urine albumin-creatinine ratio >30 mg/g) or estimated GFR <60 mL/min/1.73 m2 using the MDRD Study equation. For the Beijing study, CKD was defined as persistent albuminuria, hematuria, or estimated GFR less than 60 mL/min/1.73 m2 using an equation that computes eGFR 23% higher than the MDRD Study equation.

In this issue of AJKD, Zhang and colleagues report results from a representative sample of noninstitutionalized adults aged 18 years and older in Beijing.6 They used a similar definition of persistent albuminuria as in NHANES, but also included hematuria as a marker of kidney damage because of the higher prevalence of glomerular diseases in China than in the United States. They estimated GFR based on a serum creatinine assay traceable to IDMS and an equation which provides GFR estimates approximately 23% higher than the MDRD Study equation in whites of the same age and sex.7 They demonstrated an overall prevalence of CKD of 13%, corresponding to 1.43 million Beijing residents in 2000. Among those aged 70 years and over, the prevalence was 31% (Fig 1, left bars).

While there are many differences between the 2 studies, both highlight the substantial prevalence of CKD in the elderly, which has generated many questions and much controversy. Currently available GFR estimating equations underestimate measured GFR in the normal population and surveys do not have data on persistence of decreased GFR, so it is likely that some people with reduced estimated GFR (eGFR) do not have CKD.8 Some have suggested modification of the definition of CKD to incorporate a lower threshold for the definition of reduced GFR in the elderly.9, 10, 11 We contend that the high prevalence of reduced eGFR in the elderly is related to the high prevalence of cardiovascular disease risk factors, leading to both kidney disease and cardiovascular disease, and that reduced eGFR in the elderly should not be considered as normal, simply because it is common.

Back to Article Outline

Age-Related Changes in Kidney Function and Structure 

Normal GFR averages approximately 130 and 120 mL/min/1.73 m2 (2.7 and 2.0 mL/s/1.73 m2) in healthy young men and women, respectively, with most individuals having a GFR greater than 90 mL/min/1.73 m2 (1.50 mL/s/1.73 m2).12 In one cross-sectional study of healthy adults, a decline of approximately 10% per 10 years of age in GFR and renal blood flow was noted.13 These data gave rise to the hypothesis that a decline in GFR was a normal part of the aging process. However, a longitudinal study showed that the rate of decline in GFR was greater in people with hypertension than without.14 Among NHANES III participants, there was an increase in prevalence of albuminuria from 7% at age 20 to 39 years to 30% at age 70 years or older.15 Autopsy findings of older adults show increases in global glomerulosclerosis, arteriolar sclerosis, and tubular atrophy, with reduced cortical thickness and decreased kidney size.16, 17 These findings are considered abnormal when observed in young adults. Overall, these findings challenge the traditional concept that age-related decline in kidney function is normal.

Back to Article Outline

Consequences of CKD in the Elderly 

There is substantial evidence for health risks associated with decreased GFR and albuminuria in the elderly. The median age of new dialysis patients is now 65 years and the fastest growing group of new dialysis patients are those older than 75 years of age (Fig 2).18 Traditionally recognized complications of decreased GFR include hypertension, anemia, malnutrition, bone and mineral disorders, neuropathy, and decreased quality of life, which are common in elderly patients with eGFR less than 30 mL/min/1.73 m2 (CKD stages 4-5).15 Recent studies also demonstrate increased prevalence of traditional age-related conditions such as cognitive impairment and frailty in elderly individuals with decreased eGFR.19, 20, 21 There is a strong association between decreased eGFR or albuminuria and higher rates of cardiovascular disease and mortality in the elderly.22, 23, 24 Indeed, this is particularly true among elderly individuals with CKD, even in those with CKD stage 4. In addition, susceptibility to acute kidney injury and other side effects of medications or diagnostic and therapeutic procedures, such as imaging studies, are more common in patients with decreased GFR and are a major source of morbidity and cost in the elderly.25 In the general population, therapeutic interventions can prevent or ameliorate many of the complications of decreased GFR.26, 27, 28, 29 Comorbid conditions are frequent in the elderly, however, which may modify the effectiveness of these interventions.

  • View full-size image.
  • Figure 2. 

    Counts and rates of new cases of kidney failure treated by dialysis and transplantation, by age. Rates adjusted for sex and race. Incident rates between 2000 and 2005 have increased for patients 75 and older, compared to steady growth for most other age groups. Reproduced with permission.18

Back to Article Outline

Hypothesis: CKD in the Elderly as a Microvascular Disease 

Several lines of evidence suggest that vascular disease, specifically microvascular disease, may be an important cause of CKD in the elderly. Hypertension and diabetes are associated with specific renal vascular lesions. There are clear epidemiological associations among vascular disease risk factors, cardiovascular disease, and kidney disease. Even in the absence of clinical cardiovascular disease, there is an association among subclinical cardiovascular disease, earlier stages of CKD, inflammation, and endothelial dysfunction in the elderly.30, 31, 32 Hypertension is a well recognized risk factor for CKD and CVD in the general population. Increased pulse pressure is common in the elderly and is now recognized as a surrogate marker for aortic stiffness and a predictor for cardiovascular disease events.33 In principle, aortic stiffness is most likely to be associated with microvascular disease in high-flow, low-impedance organs, such as the kidney, where excessive pressure pulsatility is transmitted through to the microcirculation.34

Back to Article Outline

Directions for the Future 

Clinicians need to identify albuminuria and reduced eGFR in the elderly. In patients found to have CKD, all relevant characteristics must be considered in estimating prognosis and formulating treatment plans, including, cause of kidney disease, presence or absence of comorbid conditions, level of eGFR and complications related to reduced GFR, and risk factors for kidney disease progression and cardiovascular disease. In the elderly, the risk for mortality and complications is higher than for progression to kidney failure, and in many older patients, the most important interventions may be to reduce cardiovascular disease risk and avoid kidney toxicity and other side effects of medications and procedures. As outlined in the editorial by Shlipak in this issue of AJKD,35 more studies are required to better understand GFR measurement and estimation in the elderly. In addition, clinically useful predictive instruments that incorporate all of the known risk factors are needed, as are clinical trials to test the impact of therapeutic interventions on survival and quality of life in older adults with CKD.

It seems likely that nephrologists will need to care for most patients with CKD stages 4 and 5. More effective integration of principles of geriatrics into nephrology care will be necessary for this older, impaired, and frail population. In particular, this may affect the way nephrologists approach decisions regarding treatment of kidney failure and end of life care. However, nephrologists cannot and do not need to care for all patients with earlier stages of CKD. Recent clinical practice guidelines suggest detailed treatment recommendations for many of the conditions affecting patients with earlier stages of CKD as well as indications for referral, which should enable primary care physicians and other specialists to deal more effectively with many of the routine problems.15, 26, 27, 28, 29, 36, 37, 38, 39, 40

Public heath programs are beginning to include initiatives for CKD.41 As discussed in last year’s World Kidney Day editorial in AJKD, outcomes for CKD can be improved, and it is not too early to think of preventing development of CKD.1 Surveillance programs for all stages of CKD and antecedent conditions, such as NHANES in the United States and the program in Beijing reported in this issue of AJKD, are the first steps in determining the burden of CKD in the elderly.

Back to Article Outline

Acknowledgements 

Support: None.

Financial Disclosure: None.

Back to Article Outline

References 

  1. Levey A, Andreoli S, DuBose T, Provenzano R, Collins AJ. CKD: Common, harmful, and treatable—World Kidney Day 2007. Am J Kidney Dis. 2007;49:175–179
  2. Centers for Disease Control and Prevention. Public health and aging: Trends in aging—United States and worldwide. MMWR Morb Mortal Wkly Rep. 2003;52:101–106
  3. Reed D, Foley D, White L, et al. Predictors of healthy aging in men with high life expectancies. Am J Public Health. 1998;88:1463–1468
  4. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298:2038–2047
  5. Levey AS, Greene T, Stevens LA, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145:247–254
  6. Zhang L, Zhang P, Wang F, et al. Prevalence and factors associated with CKD: A population study from Beijing. Am J Kidney Dis. 2008;51:373–384
  7. Ma Y-C, Zuo L, Chen J-H, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol. 2006;17:2937–2944
  8. Stevens LA, Coresh J, Deysher AE, et al. Evaluation of the MDRD study equation in a large diverse population. J Am Soc Nephrol. 2007;18:2749–2757
  9. Coresh J, Stevens LA, and Levey AS: Chronic kidney disease is common: What do we do next? Nephrol Dial Transplant (in press)
  10. Couser WG. Chronic kidney disease the promise and the perils. J Am Soc Nephrol. 2007;18:2803–2805
  11. Glassock R, Winearls C: Epidemic of chronic kidney disease: fact or fiction. Nephrol Dial Transplant (in press)
  12. Wesson L. Physiology of the Human Kidney. New York: Grune & Stratton; 1969;
  13. Davies D, Shock N. Age changes in glomerular filtration rate, effective renal plasma flow, and tubular excretory capacity in adult males. J Clin Invest. 1950;29:496–507
  14. Lindeman R, Tobin J, Shock N. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc. 1985;33:278–285
  15. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative Am J Kidney Dis. 2002;39(suppl 1):S1–S266
  16. Kasiske B. Relationship between vascular disease and age-associated changes in the human kidney. Kidney Int. 1987;31:1153–1159
  17. Anderson S, Brenner B. Effects of aging on the renal glomerulus. Am J Med. 1986;80:435–442
  18. US Renal Data System. Excerpts from the 2007 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Am J Kidney Dis. 2008;51(suppl 1):S1–S319
  19. Kurella M, Chertow G, Fried L, et al. Chronic kidney disease and cognitive impairment in the elderly: The health, aging and body composition study. J Am Soc Nephrol. 2005;16:2127–2133
  20. Seliger S, Siscovick D, Stehman-Breen C, et al. Moderate renal impairment and risk of dementia among older adults: the Cardiovascular Health Cognition Study. J Am Soc Nephrol. 2004;15:1904–1911
  21. Shlipak M, Stehman-Breen C, Fried L, et al. The presence of frailty in elderly persons with chronic renal insufficiency. Am J Kid Dis. 2004;43:861–867
  22. Keith D, Nicholls G, Guillion C, Brown J, Smith D. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Int Med. 2004;164:659–663
  23. Shlipak MG, Sarnak MJ, Katz R, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med. 2005;352:2049–2060
  24. Astor B, Hallan S, Miller E: Glomerular filtration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the US population. Am J Epidemiol (in press)
  25. Steinman M, Landefeld C, Rosenthal G, et al. Polypharmacy and prescribing quality in older people. J Am Geriatr Soc. 2006;54:16–23
  26. National Kidney Foundation. K/DOQI clinical practice guidelines for hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43(suppl 1):S1–S268
  27. National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis. 2007;50:471–530
  28. National Kidney Foundation. K/DOQI clinical practice guidelines for nutrition in chronic renal failure. Am J Kidney Dis. 2000;35(suppl 2):S1–S140
  29. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(suppl 3):S1–S202
  30. Shlipak MG, Fried LF, Crump C, et al. Cardiovascular disease risk status in elderly persons with renal insufficiency. Kidney Int. 2002;62:997–1004
  31. Paisley K, Beaman M, Tooke J, et al. Endothelial dysfunction and inflammation in asymptomatic proteinuria. Kidney Int. 2003;63:624–633
  32. Clausen P, Jensen J, Jensen G, Borch-Johnsen K, Feldt-Rasmussen B. Elevated urinary albumin excretion is associated with impaired arterial dilatory capacity in clinically healthy subjects. Circulation. 2001;103:1869–1874
  33. Mitchell GF, Guo CY, Benjamin EJ, et al. Cross-sectional correlates of increased aortic stiffness in the community: the Framingham Heart Study. Circulation. 2007;115:2628–2636
  34. O’Rourke M, Safar ME. Relationship between aortic stiffness and microvascular disease. Hypertension. 2005;46:200–204
  35. Shlipak MG. Cystatin C: Research priorities targeted to clinical decision making. Am J Kid Dis. 2008;51:358–361
  36. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560–2572
  37. American Diabetes Association. Standards of Medical Care in Diabetes—2006. Diabetes Care. 2006;29(suppl 1):S1–S71
  38. National Kidney Foundation. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis. 2005;45(suppl 3):S1–S153
  39. National Kidney Foundation. K/DOQI clinical practice guidelines for management of dyslipidemias in chronic kidney disease. Am J Kidney Dis. 2003;41(suppl 3):S1–S92
  40. National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis. 2007;49(suppl 2):S1–S180
  41. Diabetes Project. Kidney Disease Initiative. http://www.cdc.gov/diabetes/projects/kidney.htm2007;Accessed January 9, 2008

PII: S0272-6386(08)00059-0

doi:10.1053/j.ajkd.2008.01.009

Refers to article:

  • Cystatin C: Research Priorities Targeted to Clinical Decision Making

    Michael G. Shlipak
    American Journal of Kidney Diseases March 2008 (Vol. 51, Issue 3, Pages 358-361)

  • Prevalence and Factors Associated With CKD: A Population Study From Beijing

    LuXia Zhang, PuHong Zhang, Fang Wang, Li Zuo, Ying Zhou, Ying Shi, Gang Li, ShuFang Jiao, ZeJun Liu, WanNian Liang, HaiYan Wang
    American Journal of Kidney Diseases March 2008 (Vol. 51, Issue 3, Pages 373-384)

American Journal of Kidney Diseases
Volume 51, Issue 3 , Pages 353-357, March 2008

Article Tools

* Image Usage & Resolution